Pregled bibliografske jedinice broj: 1120205
Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe
Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe // Journal of Antimicrobial Chemotherapy, 54 (2004), 6; 1045-1050 doi:10.1093/jac/dkh458 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1120205 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Trends of penicillin and erythromycin resistance
among invasive Streptococcus pneumoniae in Europe
Autori
Bruinsma, Nienke ; Kristinsson, Karl G. ; Bronzwaer, Stef ; Schrijnemakers, Paul ; Degener, John ; Tiemersma, Edine ; Hryniewicz, Waleria ; Monen, Jos ; Grundmann, Hajo
Kolaboracija
EARSS participants
Izvornik
Journal of Antimicrobial Chemotherapy (0305-7453) 54
(2004), 6;
1045-1050
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Penicillin ; erythromycin ; resistance ; invasive ; Streptococcus pneumoniae ; Europe
Sažetak
Objectives: To forecast trends in resistance to penicillin and erythromycin among Streptococcus pneumoniae in Europe. Methods: Since 1999, the European Antimicrobial Resistance Surveillance System (EARSS) has collected routine antimicrobial susceptibility test results of S. pneumoniae. To observe and predict changes of reduced susceptibility over time, we used a multinomial logistic regression model. Results: Large variations in penicillin and erythromycin non-susceptibility were observed between countries, and reduced susceptibility to erythromycin (17%) has become more frequent than reduced susceptibility to penicillin (10%) in Europe overall. An overall decrease in single penicillin non-susceptibility, but an increase in dual non-susceptibility was observed, indicating a shift of single penicillin to combined non- susceptibility with erythromycin. By 2006, the proportion of single erythromycin and dual non- susceptibility could increase to as much as 20.4% and 8.9%, respectively. Conclusions: Our results indicate that appropriately dosed beta-lactams for empirical therapy are still the treatment of choice, and that macrolides should be used with prudence.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinika za infektivne bolesti "Dr Fran Mihaljević"
Profili:
Arjana Tambić-Andrašević
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE